News | July 08, 2014

CardiAQ Valve Technologies Obtained a Stay of Further Proceedings in Neovasc’s European Patent Covering Transcatheter Mitral Valves

CardiAQ recently filed a Lawsuit against Neovasc in Germany alleging that Neovasc’s pending European patent application is based upon CardiAQ technology that Neovasc obtained from CardiAQ in 2009 and 2010 during a confidential supplier relationship

July 8, 2014 — CardiAQ Valve Technologies (CardiAQ), a leader in the field of transcatheter mitral valve implantation (TMVI), announced that the European Patent Office Legal Division issued a temporary stay of further proceedings in Neovasc’s pending European patent application covering TMVI technology. This action comes as the initial result of the lawsuit filed late June 2014 in Germany by CardiAQ against Neovasc.

CardiAQ, which performed the first ever Trans-Femoral, transcatheter mitral valve implantation procedure in June of 2012 with its self-conforming, self-anchoring implant technology, alleges that the subject matter of Neovasc’s pending European patent application is CardiAQ technology that Neovasc obtained from CardiAQ in 2009 and 2010 when the two were in a confidential supplier relationship. During that time, CardiAQ provided to Neovasc confidential information about CardiAQ’s TMVI technology so that Neovasc could fashion and attach valve tissue designed by CardiAQ to valve frames designed by CardiAQ. Without CardiAQ’s knowledge, and in express breach of the confidentiality agreement, Neovasc used that confidential CardiAQ information to not only develop a competing TMVI prosthetic, but to file patent applications on aspects of the technology in Europe and in the United States Through its pending patent applications, Neovasc is attempting to block CardiAQ from using its own technology.

In early June, CardiAQ also filed a lawsuit against Neovasc in Massachusetts in which CardiAQ seeks to preclude Neovasc from marketing a transcatheter mitral valve prosthesis that uses proprietary CardiAQ technology and from further prosecution of any U.S. patents in which Neovasc is seeking to protect confidential CardiAQ TMVI technology. That U.S. lawsuit is still in its early stages.

For more information: www.cardiaq.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Overlay Init